Nektar Therapeutics Inc. (NKTR)
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive
Nektar Therapeutics is poised for a key catalyst with upcoming REZPEG 52-week maintenance data in Alopecia Areata (AA) before April's end. My base case model projects REZPEG will achieve a probability-adjusted 28% of patients reaching SALT
Nektar Therapeutics (NASDAQ:NKTR) Hits New 1-Year High Following Better-Than-Expected Earnings
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report)'s share price reached a new 52-week high during trading on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $77.00 and last traded at $73.6150, with a volume of 441428 shares changing hands. The stock had previously closed at $70.36. The
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus
NKTR Q4 revenues and earnings beat estimates. The company focuses on rezpeg with phase III studies in atopic dermatitis planned for Q2 2026.
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.78 per share versus the Zacks Consensus Estimate of a loss of $2.76. This compares to a loss of $2.25 per share a year ago.
Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet
The mean of analysts' price targets for Nektar (NKTR) points to an 89.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can NKTR Stock Sustain Its 1,000% Rally?
Nektar stock has increased more than 100% within a week and has skyrocketed 1,000% from its 52-week low of $6.50, trading at around $71 as of February 13, 2026. The surge intensified following the company's release of 36-week maintenance data from the REZOLVE-AD Phase 2b study for rezpegaldesleukin in atopic dermatitis.
Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock?
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg
Nektar Therapeutics's results from REZOLVE-AA, a trial of rezpegaldesleukin in alopecia areata, have failed to stimulate a rally in the stock. Even with concerns about statistical significance in the trial results, the drug does look to have activity in alopecia areata. Further data is coming from the atopic dermatitis study, REZOLVE-AD in Q1 '26, and from REZOLVE-AA in early Q2'26, meaning there are catalysts ahead for NKTR.
